SCHEMBL3010409

SCHEMBL3010409

Cc1ccc(C)c(Cc2csc(N3CCN(S(=O)(=O)c4ccc(F)c(Cl)c4)CC3)n2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.46
MAPT P10636 4/20 0.46
MAPK1 P28482 2/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
KDM4E B2RXH2 3/20 0.43
HPGD P15428 1/20 0.43
LMNA P02545 5/20 0.43
TSHR P16473 4/20 0.43
GAA P10253 2/20 0.43
POLB P06746 2/20 0.43
LPAR1 Q92633 1/20 0.43
LPAR2 Q9HBW0 1/20 0.43
NPSR1 Q6W5P4 2/20 0.43
GBA1 P04062 1/20 0.42
USP2 O75604 1/20 0.40
RECQL P46063 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005748 0.92 SMN1; SMN2 (0.45) HTTMAPTMAPK1MEN1KMT2A
SCHEMBL3010663 0.92 ALDH1A1 (0.46) HTTMAPTMAPK1MEN1KMT2A
SCHEMBL3019294 0.90 TSHR (0.50) HTTMAPTMAPK1MEN1KMT2A
SCHEMBL3002719 0.89 ALDH1A1 (0.56) HTTMAPTMAPK1MEN1KMT2A
SCHEMBL3006358 0.89 ALDH1A1 (0.41) HTTMAPTMAPK1ALDH1A1SMN1; SMN2
SCHEMBL3017637 0.89 SMN1; SMN2 (0.47) HTTMAPTMEN1KMT2AALDH1A1
SCHEMBL3021257 0.88 LMNA (0.48) HTTMAPTMEN1KMT2AALDH1A1
SCHEMBL3009804 0.88 MEN1 (0.46) HTTMAPTMAPK1MEN1KMT2A
SCHEMBL3013468 0.87 HTT (0.45) HTTMAPTMAPK1MEN1KMT2A
SCHEMBL3008528 0.87 DRD2 (0.37) HTTMAPTMAPK1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed
EP-2188272-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV Remynd (BE) 2010-05-26 EP disclosed
WO-2009019295-A2 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES NV REMYND (BE) 2009-02-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTT 2/4885MAPT 18/4885MAPK1 2767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.